The evidence is based on one RCT and a high risk of bias. There is no RCTs on long-term effectiveness.
| Reference | Study type | Population | Intervention and comparison | Outcomes | Risk of bias «Dimethyl fumarate in treatment of moderate to severe plaque psoriasis: effectiveness compared to placebo»1 |
|---|---|---|---|---|---|
| MA=meta-analysis | |||||
| «Sbidian E, Chaimani A, Garcia-Doval I ym. Systemic...»1 | Network MA | RCTs of systemic and biological treatments in adults (>18 years) with moderate to
severe plaque psoriasis. N=566/138. |
Dimethylfumarate maximum daily dose of 720 mg. Placebo |
Primary: PASI-90, serious adverse effects. Secondary: PASI-75, PGA0-1, DLQI, adverse events. | Incomplete dataSelective outcome reporting |
Results
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Relative effect (95% CI) |
|---|---|---|---|---|---|
| I= intervention; C=comparison; CI=confidence interval | |||||
| «Sbidian E, Chaimani A, Garcia-Doval I ym. Systemic...»1 | 1 study (566/138) | 16 weeks | 190 (33.6) | 17 (12.3) | RR 2.73 (1.72 - 4.32) |
| Level of evidence: very low The quality of evidence is downgraded due to study limitations and imprecision. |
|||||
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Relative effect (95% CI) |
|---|---|---|---|---|---|
| I= intervention; C=comparison; CI=confidence interval | |||||
| «Sbidian E, Chaimani A, Garcia-Doval I ym. Systemic...»1 | 1 study (566/138) | 16 weeks | 110 (19.4) | 6 (4.3) | RR 4.47 (2.01 - 9.95) |
| Level of evidence: very low The quality of evidence is downgraded due to study limitations, indirectness (secondary outcome measure), and imprecision. |
|||||
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Relative effect (95% CI) |
|---|---|---|---|---|---|
| I= intervention; C=comparison; CI=confidence interval | |||||
| «Sbidian E, Chaimani A, Garcia-Doval I ym. Systemic...»1 | 1 study (566/138) | 16 weeks | Serious adverse events 17 (3.0) Adverse events 472 (83.4) |
5 (3.6) 82 (59.4) |
RR 0.83 (0.31 - 2.21) 1.4 (1.22 - 1.62) |
| Level of evidence: very low The quality of evidence is downgraded due to study limitations, indirectness (secondary outcome) and imprecision. |
|||||